Bispecific Antibodies in the Treatment of Multiple Myeloma: Expert and Patient Perspectives : Episode 10
Counseling Patients with Multiple Myeloma on the Infection Risks of BCMA-Targeting Bispecifics
The panel continues their discussion on infection risk with a look at the immunosuppressive effects of BCMA-targeting bispecifics.
EP: 1.A Patient’s Experience With a Multiple Myeloma Diagnosis
EP: 2.Resources for Patient Education
EP: 3.Patient Experience With Treatment for Multiple Myeloma and Clinical Trial Participation
EP: 4.The Role of Teclistamab in Multiple Myeloma
EP: 5.Process of Administering Teclistamab and Other Bispecific Agents
EP: 6.Step-Up Doses in Patients Receiving Teclistamab for Multiple Myeloma
EP: 7.Discussing Consent for Supportive Care Agents with Patients with Multiple Myeloma
EP: 8.Advice to Patients with Multiple Myeloma Facing Hospital Admission For Teclistamab Therapy
EP: 9.Counseling Patients Receiving Teclistamab for Multiple Myeloma on COVID Precautions
Now Viewing
EP: 10.Counseling Patients with Multiple Myeloma on the Infection Risks of BCMA-Targeting Bispecifics
EP: 11.CAR T-Cell Therapy in Multiple Myeloma and Quality of Life
EP: 12.Advice for Patients, Nurse Practitioners, and Community Oncologists on Teclistamab Therapy in Multiple Myeloma
EP: 13.Recap: Teclistamab in Multiple Myeloma: A Patient’s Journey
Recent Videos
Related Content
Navigating AE Management for Cellular Therapy Across Hematologic Cancers
Tiba Al Sagheer, PharmD, BCOP, BCACP;Rebecca Gonzalez, PharmD, BCOP, FASTCT;Syeda Saba Kareem PharmD, BCOP
August 11th 2025Podcast
A panel of clinical pharmacists discussed strategies for mitigating toxicities across different multiple myeloma, lymphoma, and leukemia populations.
